Patents by Inventor Charles M. Cohen
Charles M. Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8748378Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.Type: GrantFiled: April 4, 2011Date of Patent: June 10, 2014Assignee: Stryker CorporationInventors: Charles M. Cohen, Kuber T. Sampath, Slobodan Vukicevic
-
Patent number: 8377878Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.Type: GrantFiled: August 11, 2011Date of Patent: February 19, 2013Assignee: Stryker CorporationInventors: Kuber T. Sampath, Charles M. Cohen, Slobodan Vukicevic
-
Publication number: 20120004171Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.Type: ApplicationFiled: August 11, 2011Publication date: January 5, 2012Applicant: STRYKER CORPORATIONInventors: Kuber T. Sampath, Charles M. Cohen, Slobodan Vukicevic
-
Publication number: 20110257093Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.Type: ApplicationFiled: April 4, 2011Publication date: October 20, 2011Applicant: STRYKER CORPORATIONInventors: Charles M. Cohen, Kuber T. Sampath, Slobodan Vukicevic
-
Patent number: 8017580Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.Type: GrantFiled: March 16, 2009Date of Patent: September 13, 2011Assignee: Stryker CorporationInventors: Charles M Cohen, Kuber T. Sampath, Slobodan Vukicevic
-
Publication number: 20100291170Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.Type: ApplicationFiled: March 16, 2009Publication date: November 18, 2010Applicant: STRYKER CORPORATIONInventors: KUBER T. SAMPATH, CHARLES M. COHEN, SLOBODON VUKICEVIC
-
Publication number: 20100105621Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.Type: ApplicationFiled: August 11, 2009Publication date: April 29, 2010Inventors: Charles M. Cohen, Kuber T. Sampath, Slobodan Vukicevic
-
Patent number: 7557078Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.Type: GrantFiled: September 25, 1997Date of Patent: July 7, 2009Assignee: Stryker CorporationInventors: David C. Rueger, Thangavel Kuberasampath, Hermann Oppermann, Engin Ozkaynak, Roy H. L. Pang, Charles M. Cohen
-
Patent number: 7524817Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.Type: GrantFiled: December 17, 2004Date of Patent: April 28, 2009Assignee: Stryker CorporationInventors: Charles M. Cohen, Kuber T. Sampath, Slobodon Vukicevic
-
Patent number: 7196056Abstract: Disclosed are 1) amino acid sequence data, structural features, homologies and various other data characterizing morphogenic proteins, 2) methods of producing these proteins from natural and recombinant sources and from synthetic constructs, 3) morphogenic devices comprising these morphogenic proteins and a suitably modified tissue-specific matrix, and 4) methods of inducing non-chondrogenic tissue growth in a mammal.Type: GrantFiled: March 10, 2003Date of Patent: March 27, 2007Assignee: Curis, Inc.Inventors: Charles M. Cohen, Kuber T. Sampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger
-
Patent number: 7147839Abstract: The present invention is based on the discovery that a true tissue morphogen such as OP-1 provided systemically, alone in its mature dimeric form, or as part of a soluble complex, can induce new replacement tissue regeneration at a localized, permissive defect site distal to the site of administration. Specifically, systemically administered protein is sufficient to induce formation of new functional replacement tissue, sufficient to repair a local defect in a tissue, including skeletal or orthopedic tissues, liver, pancreas, lung, cardiac, renal, uterine, intestinal, gastrointestinal tissue. (As used herein, “orthopedic” or “skeletal” or “joint” or “chondrogenic” tissue is understood to encompass the skeletal and skeletal joint tissues: bone, cartilage, tendon, ligament, and synovial membrane tissues.Type: GrantFiled: May 29, 1998Date of Patent: December 12, 2006Assignee: Curis, Inc.Inventors: Kuber T. Sampath, Charles M. Cohen
-
Patent number: 7105638Abstract: Disclosed is a method for the isolation and purification of polypeptides expressed in host cells by recombinant DNA techniques. A fused polypeptide is produced containing a desired polypeptide fused to additional amino acids. The additional amino acids define a leader sequence having properties exploitable in purification, a hinge region, and a cleavage site. The hinge region is cysteine-free and has a secondary structure which serves to expose the cleavage site to a selected endopeptidase. The method of the invention involves the production of a fused polypeptide which may be efficiently isolated by exploiting the properties of the leader sequence, and then efficiently cleaved at the cleavage site in an appropriate aqueous environment by virtue of the influence of the hinge on the cleavage agent/cleavage site reaction and other properties of the fused polypeptide.Type: GrantFiled: February 4, 1993Date of Patent: September 12, 2006Assignee: Micromet AGInventors: James S. Huston, Marc F. Charette, Charles M. Cohen, Roberto Crea, Peter C. Keck, Hermann Oppermann, David C. Rueger, Richard J. Ridge
-
Patent number: 7060680Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: GrantFiled: January 15, 2002Date of Patent: June 13, 2006Assignee: Curis, Inc.Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Engin Ozkaynak, John E. Smart
-
Patent number: 7056882Abstract: The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.Type: GrantFiled: September 13, 2001Date of Patent: June 6, 2006Assignee: Curis, Inc.Inventors: Thangavel Kuberasampath, Charles M. Cohen, Herrmann Oppermann, Engin Ozkaynak, David C. Rueger, John E. Smart, Roy H. L. Pang
-
Patent number: 6949505Abstract: Disclosed are methods and compositions for maintaining neural pathways in a mammal including: enhancing survival of neurons at risk of dying; inducing cellular repair of damaged neurons and neural pathways; stimulating neurons to maintain their differentiated phenotype; and promoting dendritic outgrowth, including maintaining dendritic arbors and regenerating dendritic architecture. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.Type: GrantFiled: August 18, 1994Date of Patent: September 27, 2005Assignees: Curis, Inc., The Research Foundation of State University of New YorkInventors: David C. Rueger, Kuber T. Sampath, John E. Smart, Hermann Oppermann, Engin Ozkaynak, Charles M. Cohen, Dennis Higgins
-
Patent number: 6861404Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-?superfamily of proteins.Type: GrantFiled: May 6, 1997Date of Patent: March 1, 2005Assignee: Curis, Inc.Inventors: Charles M. Cohen, Kuber T. Sampath, Slobodon Vukicevic
-
Patent number: 6800603Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.Type: GrantFiled: June 16, 1994Date of Patent: October 5, 2004Assignee: Curis, Inc.Inventors: David C. Rueger, Thangavel Kuberasampath, Hermann Oppermann, Roy H. L. Pang, Charles M. Cohen
-
Publication number: 20040102373Abstract: Disclosed are 1) amino acid sequence data, structural features, homologies and various other data characterizing morphogenic proteins, 2) methods of producing these proteins from natural and recombinant sources and from synthetic constructs, 3) morphogenic devices comprising these morphogenic proteins and a suitably modified tissue-specific matrix, and 4) methods of inducing non-chondrogenic tissue growth in a mammal.Type: ApplicationFiled: March 10, 2003Publication date: May 27, 2004Applicant: Curis, Inc.Inventors: Charles M. Cohen, Kuber T. Sampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger
-
Patent number: 6723698Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.Type: GrantFiled: September 25, 1997Date of Patent: April 20, 2004Assignee: Curis, Inc.Inventors: David C. Rueger, Kuber T. Sampath, Hermann Oppermann, Roy H. L. Pang, Charles M. Cohen
-
Publication number: 20030224979Abstract: The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.Type: ApplicationFiled: September 13, 2001Publication date: December 4, 2003Inventors: Thangavel Kuberasampath, Charles M. Cohen, Herrmann Oppermann, Engin Ozkaynak, David C. Rueger, John E. Smart, Roy H.L. Pang